Abstract
An overview of adjuvant therapy in breast cancer has shown the long-term survival benefits in node-positive and-negative cases [1] (reprinted in part in this volume). However, these treatments have still made only a relatively small impact on mortality, i.e. an increase in 10-year survival from 45% to 51.3% overall and from 39.8% to 46.6% in node-positive cases. Thus, the majority still die from their cancer. Greater understanding of the mechanisms of tumour growth and metastasis may enable the rational development of new agents to complement the achievements of hormone and chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 71–85
Folkman J (1990) What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 82:4–6
Weidner MD, Semple JP, Welch WR, Folkman J (1991) Tumour angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324:1–8
Kuzu I, Bicknell R, Harris AL, Jones M, Gatter KC, Mason DY (1992) The heterogeneity of vascular endothelial cells with particular relevance to the diagnosis of vascular tumours. J Clin Pathol 45:143–148
Parums DV, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason DY (1990) JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 43:752–757
Nicholson S, Sainsbury RC, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon JR, Harris AL (1991) Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63:146–150
Bicknell R, Harris AL (1991) Novel growth regulatory factors and tumour angiogenesis. Eur J Cancer 27:781–784
Hughes CS, Irvin CG, Rockwell S (1991) Effect of deficiencies in DNA repair on the toxicity of mitomycin C and porfiromycin to CHO cells under aerobic and hypoxic conditions. Cancer Commun 3:29–35
Coleman CN (1988) Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity. J Natl Cancer Inst 80:310–317
Hoban PR, Walton MI, Robson CN, Godden J, Stratford IJ, Workman P, Harris AL, Hickson ID (1988) Mitomycin C resistance under aerobic but not hypoxic conditions in a mammalian cell line: association with impaired drug activation and decreased NADPH: cytochrome P-450 reductase activity. Cancer Res 50:775–778
Bligh HFJ, Bartoszek A, Robson CN, Hickson ID, Kasper CB, Beggs JD, Wolf CR (1990) Activation of mitomycin C by NADPH: cytochrome P-450 reductase. Cancer Res 50:7789–7792
Wireko FC, Abraham DJ (1991) X-ray diffraction study of the binding of the antisickling agent 12C79 to human hemoglobin. Proc Natl Acad Sci USA 88:2209–2211
Philip P, Harris AL, Rea D, Carmichael J, Rajagopalan B, Bedford P, Thompson C, Radda GK (1992) Phase I/II trial of left shifting agent BW12C and mitomycin C. Monitoring by magnetic resonance spectroscopy (MRS). Proc ASCO II:137
Review Issue (1991) Cell 64:235–364
Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Ohno S, Suzuki K, Tsuruo T, Cowan KH, Glazer RI (1991) Transfection with protein kinase Ca confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun 3:181–189
Nuti M, Zupi G, D’Agnano I, Turchi V, Candiloro A, Frati L (1991) Antigenic expression changes occurring in Adriamycin resistant MCF-7 mammary carcinoma cells. Anticancer Res 11:1225–1230
Andrews PA, Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2:35–43
Kawada M, Imoto M, Umezawa K (1991) Suppression of multidrug resistance by inostamycin in cultured human carcinoma KB cells. J Cell Pharmacol 2:138–142
Gschwendt M, Furstenberger G, Rose-John S, Rogers M, Kittstein W, Pettit GR, Herald CI, Marks F (1988) Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro. Carcinogenesis 9:555–562
Nutt JE, Harris AL, Lunec J (1991) Phorbol ester and bryostatin effects on growth and the expression of oestrogen responsive and TGF-ß1 genes in breast tumour cells. Br J Cancer 64:671–676
Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, Soltoff S (1991) Oncogenes and signal transduction. Cell 64:281–302
Rea D, Prendiville J, Harris AL, Wolf P, Philip P, Carmichael J, Lewis C, Dallman M, Walker T, Sri-Pathmanathan R, Thatcher N, Crowther D (1992) A phase I study of bryostatin 1 - a protein kinase C partial agonist. EORTC-NIH, New Drugs Conference, Amsterdam
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Harris, A.L., Horak, E. (1993). Growth Factors and Angiogenesis in Breast Cancer. In: Senn, HJ., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Breast Cancer IV. Recent Results in Cancer Research, vol 127. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84745-5_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-84745-5_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-84747-9
Online ISBN: 978-3-642-84745-5
eBook Packages: Springer Book Archive